NOV 25, 2018 8:06 PM PST

'Longevity protein' Improves Healing in Aging Muscles

WRITTEN BY: Nouran Amin

A downside to aging is that the skeletal muscles lose their ability to heal after muscle injury. However, a recent research study at the University of Pittsburgh identified the protein that could be responsible for serving as both the culprit and a potential therapeutic target. The protein has now been referred to as the "longevity protein" Klotho.

Learn more about the effects of aging on muscles:

 

 

The study showed that in young animals-- expression of the protein Klotho was highly found after muscle injury. However, in aged animal Klotho expression was flat. "We found that we were able to rescue, at least in part, the regenerative defect of aged skeletal muscle," says Fabrisia Ambrosio, Ph.D., lead author of the study and director of rehabilitation for UPMC International. "We saw functional levels of muscle regeneration in old animals that paralleled those of their young counterparts, suggesting that this could potentially be a therapeutic option down the road."

They particularly found that by increasing levels of Klotho in aging animals or by mitigating downstream effects of Klotho deficiency—the researchers were able to restore muscle regeneration after injury.

Findings of the study were published in Nature Communications.

Credit: SEER.Cancer.gov

The study suspected that Klotho acts through mitochondria dysfunction and so Klotho-deficient animals were given a mitochondria-targeting drug called SS-31—currently being placed in phase III clinical trials. The treated animals were observed to grow more muscle tissue at the site of muscle injury in comparison to untreated controls. Additionally, administering Klotho into aging animals after injury resulted in greater muscle mass and thus, greater better functional recovery in comparison to saline-treated counterparts.

"If you just bombard the muscle with Klotho, we do not expect to observe any functional benefit," Ambrosio said. "We've found that mimicking the timing profile we see in young animals seems to be critical. We think that this gives some insight into the therapeutic window."

Source: ScienceDaily, Nature Communications

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 20, 2020
Drug Discovery & Development
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
SEP 20, 2020
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
Almost a year into the beginnings of the COVID-19 pandemic and we still do not have a Food and Drug Administration (FDA) ...
OCT 02, 2020
Immunology
Stop the Clot: A New Antibody Treatment for Thrombosis
OCT 02, 2020
Stop the Clot: A New Antibody Treatment for Thrombosis
Blood clotting helps stem the bleeding from a wound, suppressing blood loss and stopping pathogenic microorganisms from ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
OCT 07, 2020
Technology
Millimeter-Precision Drug Delivery
OCT 07, 2020
Millimeter-Precision Drug Delivery
It is almost impossible to deliver targeted drug therapy via the bloodstream without reaching the entire brain and body ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
Loading Comments...